Semaglutide vs Liraglutide
Once-weekly successor vs once-daily original GLP-1.
| Attribute | Semaglutide GLP-1 receptor agonist | Liraglutide Saxenda, Victoza |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Weight loss and blood sugar research | First-generation daily GLP-1 agonist research |
| In plain English | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. | The original once-daily GLP-1; semaglutide is the once-weekly evolution. |
| How it works | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Activates GLP-1 receptors to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying. |
| Researchers study | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. | Type 2 diabetes, obesity, and cardiovascular outcomes. |
| Internet discussion | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. | Discussed as 'first-gen Ozempic' on GLP-1 forums. |
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.
Liraglutide
First-generation daily GLP-1 agonist research
The original once-daily GLP-1; semaglutide is the once-weekly evolution.
Activates GLP-1 receptors to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying.
Type 2 diabetes, obesity, and cardiovascular outcomes.
Discussed as 'first-gen Ozempic' on GLP-1 forums.
Liraglutide is a daily GLP-1 receptor agonist researched for glucose control and weight loss.